|
1
|
Lis H and Sharon N: Protein glycosylation.
Structural and functional aspects. Eur J Biochem. 218:1–27. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Spiro RG: Protein glycosylation: Nature,
distribution, enzymatic formation, and disease implications of
glycopeptide bonds. Glycobiology. 12:43R–56R. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arike L and Hansson GC: The Densely
O-Glycosylated MUC2 mucin protects the intestine and provides food
for the commensal bacteria. J Mol Biol. 428:3221–3229. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bennett EP, Mandel U, Clausen H, Gerken
TA, Fritz TA and Tabak LA: Control of mucin-type O-glycosylation: A
classification of the polypeptide GalNAc-transferase gene family.
Glycobiology. 22:736–756. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu CH, Hu RH, Huang MJ, Lai IR, Chen CH,
Lai HS, Wu YM and Huang MC: C1GALT1 promotes invasive phenotypes of
hepatocellular carcinoma cells by modulating integrin β1
glycosylation and activity. PLoS One. 9:e949952014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ju T and Cummings RD: A unique molecular
chaperone Cosmc required for activity of the mammalian core 1 beta
3-galactosyltransferase. Proc Natl Acad Sci USA. 99:16613–16618.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ju T, Otto VI and Cummings RD: The Tn
antigen-structural simplicity and biological complexity. Angew Chem
Int Ed Engl. 50:1770–1791. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Galvan M, Tsuboi S, Fukuda M and Baum LG:
Expression of a specific glycosyltransferase enzyme regulates T
cell death mediated by galectin-1. J Biol Chem. 275:16730–16737.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ju T, Cummings RD and Canfield WM:
Purification, characterization, and subunit structure of rat core 1
Beta1,3-galactosyltransferase. J Biol Chem. 277:169–177. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ju T, Brewer K, D'Souza A, Cummings RD and
Canfield WM: Cloning and expression of human core 1
beta1,3-galactosyltransferase. J Biol Chem. 277:178–186. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kudo T, Sato T, Hagiwara K, Kozuma Y,
Yamaguchi T, Ikehara Y, Hamada M, Matsumoto K, Ema M, Murata S, et
al: C1galt1-deficient mice exhibit thrombocytopenia due to abnormal
terminal differentiation of megakaryocytes. Blood. 122:1649–1657.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vajaria BN and Patel PS: Glycosylation: A
hallmark of cancer? Glycoconj J. 34:147–156. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Munkley J and Elliott DJ: Hallmarks of
glycosylation in cancer. Oncotarget. 7:35478–35489. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu F, Fu J, Bergstrom K, Shan X, McDaniel
JM, McGee S, Bai X, Chen W and Xia L: Core 1-derived mucin-type
O-glycosylation protects against spontaneous gastritis and gastric
cancer. J Exp Med. 217:e201823252020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chou CH, Huang MJ, Chen CH, Shyu MK, Huang
J, Hung JS, Huang CS and Huang MC: Up-regulation of C1GALT1
promotes breast cancer cell growth through MUC1-C signaling
pathway. Oncotarget. 6:6123–6135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fu J, Gerhardt H, McDaniel JM, Xia B, Liu
X, Ivanciu L, Ny A, Hermans K, Silasi-Mansat R, McGee S, et al:
Endothelial cell O-glycan deficiency causes blood/lymphatic
misconnections and consequent fatty liver disease in mice. J Clin
Invest. 118:3725–3737. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kuo TC, Wu MH, Yang SH, Chen ST, Hsu TW,
Jhuang JY, Liao YY, Tien YW and Huang MC: C1GALT1 high expression
is associated with poor survival of patients with pancreatic ductal
adenocarcinoma and promotes cell invasiveness through integrin αv.
Oncogene. 40:1242–1254. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee PC, Chen ST, Kuo TC, Lin TC, Lin MC,
Huang J, Hung JS, Hsu CL, Juan HF, Lee PH and Huang MC: C1GALT1 is
associated with poor survival and promotes soluble Ephrin
A1-mediated cell migration through activation of EPHA2 in gastric
cancer. Oncogene. 39:2724–2740. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin MC, Chien PH, Wu HY, Chen ST, Juan HF,
Lou PJ and Huang MC: C1GALT1 predicts poor prognosis and is a
potential therapeutic target in head and neck cancer. Oncogene.
37:5780–5793. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dong X, Luo Z, Wang Y, Meng L, Duan Q, Qiu
L, Peng F and Shen L: Altered O-glycosylation is associated with
inherent radioresistance and malignancy of human laryngeal
carcinoma. Exp Cell Res. 362:302–310. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chou CH, Huang MJ, Liao YY, Chen CH and
Huang MC: C1GALT1 seems to promote in vitro disease progression in
ovarian cancer. Int J Gynecol Cancer. 27:863–871. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu YM, Liu CH, Huang MJ, Lai HS, Lee PH,
Hu RH and Huang MC: C1GALT1 enhances proliferation of
hepatocellular carcinoma cells via modulating MET glycosylation and
dimerization. Cancer Res. 73:5580–5590. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Karsten U and Goletz S: What controls the
expression of the core-1 (Thomsen-Friedenreich) glycotope on tumor
cells? Biochemistry (Mosc). 80:801–807. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Numa F, Tsunaga N, Michioka T, Nawata S,
Ogata H and Kato H: Tissue expression of Sialyl Tn antigen in
gynecologic tumors. J Obstet Gynaecol (Tokyo 1995). 21:385–389.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Laack E, Nikbakht H, Peters A, Kugler C,
Jasiewicz Y, Edler L, Hossfeld DK and Schumacher U: Lectin
histochemistry of resected adenocarcinoma of the lung: Helix
pomatia agglutinin binding is an independent prognostic factor. Am
J Pathol. 160:1001–1008. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Konno A, Hoshino Y, Terashima S, Motoki R
and Kawaguchi T: Carbohydrate expression profile of colorectal
cancer cells is relevant to metastatic pattern and prognosis. Clin
Exp Metastasis. 19:61–70. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Suzuki H, Moldoveanu Z, Hall S, Brown R,
Vu HL, Novak L, Julian BA, Tomana M, Wyatt RJ, Edberg JC, et al:
IgA1-secreting cell lines from patients with IgA nephropathy
produce aberrantly glycosylated IgA1. J Clin Invest. 118:629–639.
2008.PubMed/NCBI
|
|
29
|
Narimatsu Y, Kubota T, Furukawa S,
Shimojima M, Iwasaki H, Tozawa Y, Tachibana K and Narimatsu H:
Co-translational function of Cosmc, core 1 synthase specific
molecular chaperone, revealed by a cell-free translation system.
FEBS Lett. 585:1276–1280. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alexander WS, Viney EM, Zhang JG, Metcalf
D, Kauppi M, Hyland CD, Carpinelli MR, Stevenson W, Croker BA,
Hilton AA, et al: Thrombocytopenia and kidney disease in mice with
a mutation in the C1galt1 gene. Proc Natl Acad Sci USA.
103:16442–16447. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Piller V, Piller F and Fukuda M:
Biosynthesis of truncated O-glycans in the T cell line Jurkat.
Localization of O-glycan initiation. J Biol Chem. 265:9264–9271.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ju T, Lanneau GS, Gautam T, Wang Y, Xia B,
Stowell SR, Willard MT, Wang W, Xia JY, Zuna RE, et al: Human tumor
antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer
Res. 68:1636–1646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aryal RP, Ju T and Cummings RD: Tight
complex formation between Cosmc chaperone and its specific client
non-native T-synthase leads to enzyme activity and client-driven
dissociation. J Biol Chem. 287:15317–15329. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Aryal RP, Ju T and Cummings RD: The
endoplasmic reticulum chaperone Cosmc directly promotes in vitro
folding of T-synthase. J Biol Chem. 285:2456–2462. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ellis RJ: The molecular chaperone concept.
Semin Cell Biol. 1:1–9. 1990.PubMed/NCBI
|
|
36
|
Ju T, Aryal RP, Stowell CJ and Cummings
RD: Regulation of protein O-glycosylation by the endoplasmic
reticulum-localized molecular chaperone Cosmc. J Cell Biol.
182:531–542. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ju T and Cummings RD: Protein
glycosylation: Chaperone mutation in Tn syndrome. Nature.
437:12522005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fidler IJ: The pathogenesis of cancer
metastasis: The ‘seed and soil’ hypothesis revisited. Nat Rev
Cancer. 3:453–458. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
An G, Wei B, Xia B, McDaniel JM, Ju T,
Cummings RD, Braun J and Xia L: Increased susceptibility to colitis
and colorectal tumors in mice lacking core 3-derived O-glycans. J
Exp Med. 204:1417–1429. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guda K, Moinova H, He J, Jamison O, Ravi
L, Natale L, Lutterbaugh J, Lawrence E, Lewis S, Willson JK, et al:
Inactivating germ-line and somatic mutations in polypeptide
N-acetylgalactosaminyltransferase 12 in human colon cancers. Proc
Natl Acad Sci USA. 106:12921–12925. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Brockhausen I: Pathways of O-glycan
biosynthesis in cancer cells. Biochim Biophys Acta. 1473:67–95.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shin S, Jung Y, Uhm H, Song M, Son S, Goo
J, Jeong C, Song JJ, Kim VN and Hohng S: Quantification of purified
endogenous miRNAs with high sensitivity and specificity. Nat
Commun. 11:60332020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Saliminejad K, Khorram Khorshid HR,
Soleymani Fard S and Ghaffari SH: An overview of microRNAs:
Biology, functions, therapeutics, and analysis methods. J Cell
Physiol. 234:5451–5465. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Condrat CE, Thompson DC, Barbu MG, Bugnar
OL, Boboc A, Cretoiu D, Suciu N, Cretoiu SM and Voinea SC: miRNAs
as biomarkers in disease: Latest findings regarding their role in
diagnosis and prognosis. Cells. 9:2762020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen H, Xiao Z, Yu R, Wang Y, Xu R and Zhu
X: miR-181d-5p-FOXP1 feedback loop modulates the progression of
osteosarcoma. Biochem Biophys Res Commun. 503:1434–1441. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang H, Wei H, Wang J, Li L, Chen A and Li
Z: MicroRNA-181d-5p-containing exosomes derived from CAFs promote
EMT by regulating CDX2/HOXA5 in breast cancer. Mol Ther Nucleic
Acids. 19:654–667. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gao LM, Zheng Y, Wang P, Zheng L, Zhang
WL, Di Y, Chen LL, Yin XB, Tian Q, Shi SS and Xu SF:
Tumor-suppressive effects of microRNA-181d-5p on non-small-cell
lung cancer through the CDKN3-mediated Akt signaling pathway in
vivo and in vitro. Am J Physiol Lung Cell Mol Physiol.
316:L918–L933. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dong X, Liu Y, Deng X, Shao J, Tian S,
Chen S, Huang R, Lin Z, Chen C and Shen L: C1GALT1, negatively
regulated by miR-181d-5p, promotes tumor progression via
upregulating RAC1 in lung adenocarcinoma. Front Cell Dev Biol.
9:7079702021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Feng F, Liu H, Chen A, Xia Q, Zhao Y, Jin
X and Huang J: miR-148-3p and miR-152-3p synergistically regulate
prostate cancer progression via repressing KLF4. J Cell Biochem.
120:17228–17239. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sun J, Tian X, Zhang J, Huang Y, Lin X,
Chen L and Zhang S: Regulation of human glioma cell apoptosis and
invasion by miR-152-3p through targeting DNMT1 and regulating NF2:
MiR-152-3p regulate glioma cell apoptosis and invasion. J Exp Clin
Cancer Res. 36:1002017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ma P, Li L, Liu F and Zhao Q:
HNF1A-induced lncRNA HCG18 facilitates gastric cancer progression
by upregulating DNAJB12 via miR-152-3p. Onco Targets Ther.
13:7641–7652. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Dong X, Chen C, Deng X, Liu Y, Duan Q,
Peng Z, Luo Z and Shen L: A novel mechanism for C1GALT1 in the
regulation of gastric cancer progression. Cell Biosci. 11:1662021.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Nguyen LK, Kholodenko BN and von
Kriegsheim A: Rac1 and RhoA: Networks, loops and bistability. Small
GTPases. 9:316–321. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zou T, Mao X, Yin J, Li X, Chen J, Zhu T,
Li Q, Zhou H and Liu Z: Emerging roles of RAC1 in treating lung
cancer patients. Clin Genet. 91:520–528. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
De P, Aske JC and Dey N: RAC1 Takes the
lead in solid tumors. Cells. 8:3822019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kazanietz MG and Caloca MJ: The Rac GTPase
in Cancer: From old concepts to new paradigms. Cancer Res.
77:5445–5451. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chen L, Zhang D, Ding T, Liu F, Xu X, Tian
Y, Xiao J and Shen H: LncRNA NR2F2-AS1 upregulates Rac1 to increase
cancer stemness in clear cell renal cell carcinoma. Cancer Biother
Radiopharm. 35:301–306. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zeng Y, Ren M, Li Y, Chen C, Su J, Su B,
Xia H, Liu F, Jiang H, Ling H, et al: Knockdown of RhoGDI2
represses human gastric cancer cell proliferation, invasion and
drug resistance via the Rac1/Pak1/LIMK1 pathway. Cancer Lett.
492:136–146. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chen HH, Yu HI, Cho WC and Tarn WY: DDX3
modulates cell adhesion and motility and cancer cell metastasis via
Rac1-mediated signaling pathway. Oncogene. 34:2790–2800. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Hung JS, Huang J, Lin YC, Huang MJ, Lee
PH, Lai HS, Liang JT and Huang MC: C1GALT1 overexpression promotes
the invasive behavior of colon cancer cells through modifying
O-glycosylation of FGFR2. Oncotarget. 5:2096–2106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Liu SY, Shun CT, Hung KY, Juan HF, Hsu CL,
Huang MC and Lai IR: Mucin glycosylating enzyme GALNT2 suppresses
malignancy in gastric adenocarcinoma by reducing MET
phosphorylation. Oncotarget. 7:11251–11262. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Wu YM, Liu CH, Hu RH, Huang MJ, Lee JJ,
Chen CH, Huang J, Lai HS, Lee PH, Hsu WM, et al: Mucin
glycosylating enzyme GALNT2 regulates the malignant character of
hepatocellular carcinoma by modifying the EGF receptor. Cancer Res.
71:7270–7279. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Huang MJ, Hu RH, Chou CH, Hsu CL, Liu YW,
Huang J, Hung JS, Lai IR, Juan HF, Yu SL, et al: Knockdown of
GALNT1 suppresses malignant phenotype of hepatocellular carcinoma
by suppressing EGFR signaling. Oncotarget. 6:5650–5665. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Bradley CA, Salto-Tellez M, Laurent-Puig
P, Bardelli A, Rolfo C, Tabernero J, Khawaja HA, Lawler M, Johnston
PG and Van Schaeybroeck S; MErCuRIC consortium, : Targeting c-MET
in gastrointestinal tumours: Rationale, opportunities and
challenges. Nat Rev Clin Oncol. 14:562–576. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Sierra JC, Asim M, Verriere TG, Piazuelo
MB, Suarez G, Romero-Gallo J, Delgado AG, Wroblewski LE, Barry DP,
Peek RM Jr, et al: Epidermal growth factor receptor inhibition
downregulates-induced epithelial inflammatory responses, DNA damage
and gastric carcinogenesis. Gut. 67:1247–1260. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kania A and Klein R: Mechanisms of
ephrin-Eph signalling in development, physiology and disease. Nat
Rev Mol Cell Biol. 17:240–256. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Xi HQ, Wu XS, Wei B and Chen L: Eph
receptors and ephrins as targets for cancer therapy. J Cell Mol
Med. 16:2894–2909. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Vaught D, Brantley-Sieders DM and Chen J:
Eph receptors in breast cancer: Roles in tumor promotion and tumor
suppression. Breast Cancer Res. 10:2172008. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Herath NI and Boyd AW: The role of Eph
receptors and ephrin ligands in colorectal cancer. Int J Cancer.
126:2003–2011. 2010.PubMed/NCBI
|
|
70
|
Lisle JE, Mertens-Walker I, Rutkowski R,
Herington AC and Stephenson SA: Eph receptors and their ligands:
Promising molecular biomarkers and therapeutic targets in prostate
cancer. Biochim Biophys Acta. 1835:243–257. 2013.PubMed/NCBI
|
|
71
|
Pasquale EB: Eph receptors and ephrins in
cancer: Bidirectional signalling and beyond. Nat Rev Cancer.
10:165–180. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Boyd AW, Bartlett PF and Lackmann M:
Therapeutic targeting of EPH receptors and their ligands. Nat Rev
Drug Discov. 13:39–62. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Yuan WJ, Ge J, Chen ZK, Wu SB, Shen H,
Yang P, Hu B, Zhang GW and Chen ZH: Over-expression of EphA2 and
EphrinA-1 in human gastric adenocarcinoma and its prognostic value
for postoperative patients. Dig Dis Sci. 54:2410–2417. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Nakamura R, Kataoka H, Sato N, Kanamori M,
Ihara M, Igarashi H, Ravshanov S, Wang YJ, Li ZY, Shimamura T, et
al: EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci.
96:42–47. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Yuan W, Chen Z, Chen Z, Wu S, Guo J, Ge J,
Yang P and Huang J: Silencing of EphA2 inhibits invasion of human
gastric cancer SGC-7901 cells in vitro and in vivo. Neoplasma.
59:105–113. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zender L, Villanueva A, Tovar V, Sia D,
Chiang DY and Llovet JM: Cancer gene discovery in hepatocellular
carcinoma. J Hepatol. 52:921–929. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Marquardt JU, Galle PR and Teufel A:
Molecular diagnosis and therapy of hepatocellular carcinoma (HCC):
An emerging field for advanced technologies. J Hepatol. 56:267–275.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Herr P, Korniychuk G, Yamamoto Y, Grubisic
K and Oelgeschläger M: Regulation of TGF-(beta) signalling by
N-acetylgalactosaminyltransferase-like 1. Development.
135:1813–1822. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Kaposi-Novak P, Lee JS, Gòmez-Quiroz L,
Coulouarn C, Factor VM and Thorgeirsson SS: Met-regulated
expression signature defines a subset of human hepatocellular
carcinomas with poor prognosis and aggressive phenotype. J Clin
Invest. 116:1582–1595. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu
MY, Xu Y, Song ZJ, Wang ZJ, Wu JC, et al: Role of overexpression of
CD151 and/or c-Met in predicting prognosis of hepatocellular
carcinoma. Hepatology. 49:491–503. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
D'Errico A, Fiorentino M, Ponzetto A,
Daikuhara Y, Tsubouchi H, Brechot C, Scoazec JY and Grigioni WF:
Liver hepatocyte growth factor does not always correlate with
hepatocellular proliferation in human liver lesions: Its specific
receptor c-met does. Hepatology. 24:60–64. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Ma PC, Maulik G, Christensen J and Salgia
R: c-Met: Structure, functions and potential for therapeutic
inhibition. Cancer Metastasis Rev. 22:309–325. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Birchmeier C, Birchmeier W, Gherardi E and
Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol
Cell Biol. 4:915–925. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Casaletto JB and McClatchey AI: Spatial
regulation of receptor tyrosine kinases in development and cancer.
Nat Rev Cancer. 12:387–400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Matsuda Y, Ueda J and Ishiwata T:
Fibroblast growth factor receptor 2: Expression, roles, and
potential as a novel molecular target for colorectal cancer.
Patholog Res Int. 2012:5747682012.PubMed/NCBI
|
|
86
|
Hatch NE, Hudson M, Seto ML, Cunningham ML
and Bothwell M: Intracellular retention, degradation, and signaling
of glycosylation-deficient FGFR2 and craniosynostosis
syndrome-associated FGFR2C278F. J Biol Chem. 281:27292–27305. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Schlessinger J: Ligand-induced,
receptor-mediated dimerization and activation of EGF receptor.
Cell. 110:669–672. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Leemans CR, Snijders PJF and Brakenhoff
RH: The molecular landscape of head and neck cancer. Nat Rev
Cancer. 18:269–282. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Tsai CH, Tzeng SF, Chao TK, Tsai CY, Yang
YC, Lee MT, Hwang JJ, Chou YC, Tsai MH, Cha TL and Hsiao PW:
Metastatic progression of prostate cancer is mediated by autonomous
binding of Galectin-4-O-Glycan to cancer cells. Cancer Res.
76:5756–5767. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Marcucci F, Bellone M, Caserta CA and
Corti A: Pushing tumor cells towards a malignant phenotype: Stimuli
from the microenvironment, intercellular communications and
alternative roads. Int J Cancer. 135:1265–1276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Guo W and Giancotti FG: Integrin
signalling during tumour progression. Nat Rev Mol Cell Biol.
5:816–826. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Mueller MM and Fusenig NE: Friends or
foes-bipolar effects of the tumour stroma in cancer. Nat Rev
Cancer. 4:839–849. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Hood JD and Cheresh DA: Role of integrins
in cell invasion and migration. Nat Rev Cancer. 2:91–100. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Fransvea E, Mazzocca A, Antonaci S and
Giannelli G: Targeting transforming growth factor (TGF)-betaRI
inhibits activation of beta1 integrin and blocks vascular invasion
in hepatocellular carcinoma. Hepatology. 49:839–850. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Yang C, Zeisberg M, Lively JC, Nyberg P,
Afdhal N and Kalluri R: Integrin alpha1beta1 and alpha2beta1 are
the key regulators of hepatocarcinoma cell invasion across the
fibrotic matrix microenvironment. Cancer Res. 63:8312–8317.
2003.PubMed/NCBI
|
|
96
|
Ke AW, Shi GM, Zhou J, Huang XY, Shi YH,
Ding ZB, Wang XY, Devbhandari RP and Fan J: CD151 amplifies
signaling by integrin α6β1 to PI3K and induces the
epithelial-mesenchymal transition in HCC cells. Gastroenterology.
140:1629–1641.e15. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Lee SH, Hatakeyama S, Yu SY, Bao X, Ohyama
C, Khoo KH, Fukuda MN and Fukuda M: Core3 O-glycan synthase
suppresses tumor formation and metastasis of prostate carcinoma PC3
and LNCaP cells through down-regulation of alpha2beta1 integrin
complex. J Biol Chem. 284:17157–17169. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Clément M, Rocher J, Loirand G and Le
Pendu J: Expression of sialyl-Tn epitopes on beta1 integrin alters
epithelial cell phenotype, proliferation and haptotaxis. J Cell
Sci. 117:5059–5069. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Liao WC, Chen CH, Liu CH, Huang MJ, Chen
CW, Hung JS, Chou CH, Chen CH, Che MI, Chang HM, et al: Expression
of GALNT2 in human extravillous trophoblasts and its suppressive
role in trophoblast invasion. Placenta. 33:1005–1011. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Huang MC, Chen HY, Huang HC, Huang J,
Liang JT, Shen TL, Lin NY, Ho CC, Cho IM and Hsu SM: C2GnT-M is
downregulated in colorectal cancer and its re-expression causes
growth inhibition of colon cancer cells. Oncogene. 25:3267–3276.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Park JH, Katagiri T, Chung S, Kijima K and
Nakamura Y: Polypeptide N-acetylgalactosaminyltransferase 6
disrupts mammary acinar morphogenesis through O-glycosylation of
fibronectin. Neoplasia. 13:320–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Zhang H, Meng F, Wu S, Kreike B, Sethi S,
Chen W, Miller FR and Wu G: Engagement of I-branching {beta}-1,
6-N-acetylglucosaminyltransferase 2 in breast cancer metastasis and
TGF-{beta} signaling. Cancer Res. 71:4846–4856. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Chang HH, Chen CH, Chou CH, Liao YF, Huang
MJ, Chen YH, Wang WJ, Huang J, Hung JS, Ho WL, et al:
β-1,4-Galactosyltransferase III enhances invasive phenotypes via
β1-integrin and predicts poor prognosis in neuroblastoma. Clin
Cancer Res. 19:1705–1716. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Seguin L, Desgrosellier JS, Weis SM and
Cheresh DA: Integrins and cancer: Regulators of cancer stemness,
metastasis, and drug resistance. Trends Cell Biol. 25:234–240.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Desgrosellier JS and Cheresh DA: Integrins
in cancer: Biological implications and therapeutic opportunities.
Nat Rev Cancer. 10:9–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Marsico G, Russo L, Quondamatteo F and
Pandit A: Glycosylation and integrin regulation in cancer. Trends
Cancer. 4:537–552. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Ju JA, Godet I, Ye IC, Byun J, Jayatilaka
H, Lee SJ, Xiang L, Samanta D, Lee MH, Wu PH, et al: Hypoxia
selectively enhances integrin αβ receptor expression in breast
cancer to promote metastasis. Mol Cancer Res. 15:723–734. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Li XQ, Lu JT, Tan CC, Wang QS and Feng YM:
RUNX2 promotes breast cancer bone metastasis by increasing integrin
α5-mediated colonization. Cancer Lett. 380:78–86. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Pantano F, Croset M, Driouch K,
Bednarz-Knoll N, Iuliani M, Ribelli G, Bonnelye E, Wikman H, Geraci
S, Bonin F, et al: Integrin alpha5 in human breast cancer is a
mediator of bone metastasis and a therapeutic target for the
treatment of osteolytic lesions. Oncogene. 40:1284–1299. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Wang JF, Wang Y, Zhang SW, Chen YY, Qiu Y,
Duan SY, Li BP and Chen JQ: Expression and prognostic analysis of
integrins in gastric cancer. J Oncol. 2020:88622282020. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Hakamada K: Cancer stroma-targeting
therapy: A new tool for fighting pancreatic cancer? Ann
Gastroenterol Surg. 3:120–121. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Guan JL: Role of focal adhesion kinase in
integrin signaling. Int J Biochem Cell Biol. 29:1085–1096. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Mitra SK, Mikolon D, Molina JE, Hsia DA,
Hanson DA, Chi A, Lim ST, Bernard-Trifilo JA, Ilic D, Stupack DG,
et al: Intrinsic FAK activity and Y925 phosphorylation facilitate
an angiogenic switch in tumors. Oncogene. 25:5969–5984. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Chen CH, Shyu MK, Wang SW, Chou CH, Huang
MJ, Lin TC, Chen ST, Lin HH and Huang MC: MUC20 promotes aggressive
phenotypes of epithelial ovarian cancer cells via activation of the
integrin β1 pathway. Gynecol Oncol. 140:131–137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Guan JL: Integrin signaling through FAK in
the regulation of mammary stem cells and breast cancer. IUBMB Life.
62:268–276. 2010.PubMed/NCBI
|
|
116
|
Nath S and Mukherjee P: MUC1: A
multifaceted oncoprotein with a key role in cancer progression.
Trends Mol Med. 20:332–342. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Taylor-Papadimitriou J, Burchell JM,
Plunkett T, Graham R, Correa I, Miles D and Smith M: MUC1 and the
immunobiology of cancer. J Mammary Gland Biol Neoplasia. 7:209–221.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Kufe DW: Mucins in cancer: Function,
prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Apostolopoulos V, Stojanovska L and
Gargosky SE: MUC1 (CD227): A multi-tasked molecule. Cell Mol Life
Sci. 72:4475–4500. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Chen CH, Wang SW, Chen CW, Huang MR, Hung
JS, Huang HC, Lin HH, Chen RJ, Shyu MK and Huang MC: MUC20
overexpression predicts poor prognosis and enhances EGF-induced
malignant phenotypes via activation of the EGFR-STAT3 pathway in
endometrial cancer. Gynecol Oncol. 128:560–567. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Chen CH, Hsiao SM, Chang TC, Wu WY and Lin
HH: Clinical and urodynamic effects of baclofen in women with
functional bladder outlet obstruction: Preliminary report. J Obstet
Gynaecol Res. 42:560–565. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Pinho SS and Reis CA: Glycosylation in
cancer: Mechanisms and clinical implications. Nat Rev Cancer.
15:540–555. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Razawi H, Kinlough CL, Staubach S, Poland
PA, Rbaibi Y, Weisz OA, Hughey RP and Hanisch FG: Evidence for core
2 to core 1 O-glycan remodeling during the recycling of MUC1.
Glycobiology. 23:935–945. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Kufe DW: MUC1-C oncoprotein as a target in
breast cancer: Activation of signaling pathways and therapeutic
approaches. Oncogene. 32:1073–1081. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Xu HL, Zhao X, Zhang KM, Tang W and Kokudo
N: Inhibition of KL-6/MUC1 glycosylation limits aggressive
progression of pancreatic cancer. World J Gastroenterol.
20:12171–12181. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Wang Y, Liao X, Ye Q and Huang L: Clinic
implication of MUC1 O-glycosylation and C1GALT1 in esophagus
squamous cell carcinoma. Sci China Life Sci. 61:1389–1395. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Gendler SJ, Spicer AP, Lalani EN, Duhig T,
Peat N, Burchell J, Pemberton L, Boshell M and Taylor-Papadimitriou
J: Structure and biology of a carcinoma-associated mucin, MUC1. Am
Rev Respir Dis. 144 (Suppl 1):S42–S47. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Posey AD, Schwab RD, Boesteanu AC,
Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K,
Haines KM, et al: Engineered CAR T cells targeting the
cancer-associated Tn-glycoform of the membrane mucin MUC1 control
adenocarcinoma. Immunity. 44:1444–1454. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Kato T, Ujiie H, Hatanaka KC, Nange A,
Okumura A, Tsubame K, Naruchi K, Sato M, Kaga K, Matsuno Y, et al:
A novel Tn antigen epitope-recognizing antibody for MUC1 predicts
clinical outcome in patients with primary lung adenocarcinoma.
Oncol Lett. 21:2022021. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Allen A, Hutton DA and Pearson JP: The
MUC2 gene product: A human intestinal mucin. Int J Biochem Cell
Biol. 30:797–801. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Tytgat KM, Büller HA, Opdam FJ, Kim YS,
Einerhand AW and Dekker J: Biosynthesis of human colonic mucin:
Muc2 is the prominent secretory mucin. Gastroenterology.
107:1352–1363. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
van Klinken BJ, Einerhand AW, Duits LA,
Makkink MK, Tytgat KM, Renes IB, Verburg M, Büller HA and Dekker J:
Gastrointestinal expression and partial cDNA cloning of murine
Muc2. Am J Physiol. 276:G115–G124. 1999.PubMed/NCBI
|
|
133
|
Johansson MEV, Phillipson M, Petersson J,
Velcich A, Holm L and Hansson GC: The inner of the two Muc2
mucin-dependent mucus layers in colon is devoid of bacteria. Proc
Natl Acad Sci USA. 105:15064–15069. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Bergstrom K, Fu J, Johansson ME, Liu X,
Gao N, Wu Q, Song J, McDaniel JM, McGee S, Chen W, et al: Core 1-
and 3-derived O-glycans collectively maintain the colonic mucus
barrier and protect against spontaneous colitis in mice. Mucosal
Immunol. 10:91–103. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Bergstrom K, Liu X, Zhao Y, Gao N, Wu Q,
Song K, Cui Y, Li Y, McDaniel JM, McGee S, et al: Defective
intestinal Mucin-type O-Glycosylation causes spontaneous
colitis-associated cancer in mice. Gastroenterology.
151:152–164.e11. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Gao N, Bergstrom K, Fu J, Xie B, Chen W
and Xia L: Loss of intestinal O-glycans promotes spontaneous
duodenal tumors. Am J Physiol Gastrointest Liver Physiol.
311:G74–G83. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Johansson MEV, Sjövall H and Hansson GC:
The gastrointestinal mucus system in health and disease. Nat Rev
Gastroenterol Hepatol. 10:352–361. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Chugh S, Barkeer S, Rachagani S,
Nimmakayala RK, Perumal N, Pothuraju R, Atri P, Mahapatra S, Thapa
I, Talmon GA, et al: Disruption of C1galt1 Gene promotes
development and metastasis of pancreatic adenocarcinomas in mice.
Gastroenterology. 155:1608–1624. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
da Fonseca LM, da Silva VA, Freire-de-Lima
L, Previato JO, Mendonça-Previato L and Capella MAM: Glycosylation
in Cancer: Interplay between Multidrug resistance and
Epithelial-to-Mesenchymal Transition? Front Oncol. 6:1582016.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Ma H, Miao X, Ma Q, Zheng W, Zhou H and
Jia L: Functional roles of glycogene and N-glycan in multidrug
resistance of human breast cancer cells. IUBMB Life. 65:409–422.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Wu J, Qin H, Li T, Cheng K, Dong J, Tian
M, Chai N, Guo H, Li J, You X, et al: Characterization of
site-specific glycosylation of secreted proteins associated with
multi-drug resistance of gastric cancer. Oncotarget. 7:25315–25327.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Huang C, Huang M, Chen W, Zhu W, Meng H,
Guo L, Wei T and Zhang J: N-acetylglucosaminyltransferase V
modulates radiosensitivity and migration of small cell lung cancer
through epithelial-mesenchymal transition. FEBS J. 282:4295–4306.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Zhuo E, He J, Wei T, Zhu W, Meng H, Li Y,
Guo L and Zhang J: Down-regulation of GnT-V enhances nasopharyngeal
carcinoma cell CNE-2 radiosensitivity in vitro and in vivo. Biochem
Biophys Res Commun. 424:554–562. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Park JJ and Lee M: Increasing the α 2, 6
sialylation of glycoproteins may contribute to metastatic spread
and therapeutic resistance in colorectal cancer. Gut Liver.
7:629–641. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Shen L, Dong XX, Wu JB, Qiu L, Duan QW and
Luo ZG: Radiosensitisation of human glioma cells by inhibition of
β1,6-GlcNAc branched N-glycans. Tumour Biol. 37:4909–4918. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Zhang C, Deng X, Qiu L, Peng F, Geng S,
Shen L and Luo Z: Knockdown of C1GalT1 inhibits radioresistance of
human esophageal cancer cells through modifying β1-integrin
glycosylation. J Cancer. 9:2666–2677. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Moncharmont C, Levy A, Guy JB, Falk AT,
Guilbert M, Trone JC, Alphonse G, Gilormini M, Ardail D, Toillon
RA, et al: Radiation-enhanced cell migration/invasion process: A
review. Crit Rev Oncol Hematol. 92:133–142. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Paquette B, Therriault H, Desmarais G,
Wagner R, Royer R and Bujold R: Radiation-enhancement of MDA-MB-231
breast cancer cell invasion prevented by a cyclooxygenase-2
inhibitor. Br J Cancer. 105:534–541. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Qian LW, Mizumoto K, Urashima T, Nagai E,
Maehara N, Sato N, Nakajima M and Tanaka M: Radiation-induced
increase in invasive potential of human pancreatic cancer cells and
its blockade by a matrix metalloproteinase inhibitor, CGS27023.
Clin Cancer Res. 8:1223–1227. 2002.PubMed/NCBI
|
|
150
|
Wu J, Li Y, Dang YZ, Gao HX, Jiang JL and
Chen ZN: HAb18G/CD147 promotes radioresistance in hepatocellular
carcinoma cells: A potential role for integrin β1 signaling. Mol
Cancer Ther. 14:553–563. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Aftab BT, Dobromilskaya I, Liu JO and
Rudin CM: Itraconazole inhibits angiogenesis and tumor growth in
non-small cell lung cancer. Cancer Res. 71:6764–6772. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Kim J, Tang JY, Gong R, Kim J, Lee JJ,
Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, et al:
Itraconazole, a commonly used antifungal that inhibits Hedgehog
pathway activity and cancer growth. Cancer Cell. 17:388–399. 2010.
View Article : Google Scholar : PubMed/NCBI
|
